Maravai LifeSciences (MRVI) is a public company. Maravai brands set the standard in nucleic acid products and services, enzyme development, and biologics safety testing. From producing revolutionary mRNA technologies that drive infectious disease vaccines, cancer vaccines, and other cell and gene therapies to delivering gold-standard bioprocess impurity detection solutions, Maravai is helping life sciences companies overcome their biggest development and manufacturing challenges to streamline and scale from research through clinical trials to commercialization.

For over 35 years, Maravai’s brands have served as proven catalysts for innovative, lifesaving technology for humanity. Across our portfolio of brands, we hold numerous patents and offer more than 1,500 innovative products and services, including CleanCap® technology, CleanAmp® hot start PCR, Antibody Affinity Extraction™, EndonucleaseGTP®, PROTEIN A MIX-N-GO™, MockV®, Sterling™, Glen Pak™, Glen Gel-Pak™.

Each of our brands are ISO-9001:2015 certified and have earned hundreds of thousands of citations in peer-reviewed scientific publications. Founded in 2014. It has 85 employees. IPO 2020.

Transcript

Operator

Hello and welcome everyone joining today's Maravai LifeSciences Q2 2026 results earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star one on your telephone keypad. Please note this call is being recorded and we are standing by should you need any assistance. It is now my pleasure to turn the meeting over to Deb Hart. Please go ahead.

Deb Hart — Head of Investor Relations

Good afternoon, everyone. Thanks for joining us for our second quarter 2026 earnings call. The press release and slides accompanying today's call are available at investors.maravai.com. As you can see from the agenda on slide two, our CEO, Bernd Brust, will provide a business update, and our CFO, Raj Asarpota, will review our financial results. Dr. Chanfeng Zhao, our Chief Scientific Officer, and Kurt Oreshack, our Executive Vice President and General Counsel, will join us for the Q&A session. Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. Actual results could differ materially from expectations. We will undertake no